The Galien Foundation Announces 2025 Prix Galien UK Award Candidates for "Best Biotechnology Product," "Best Digital Health Solution," "Best Medical Technology," "Best Pharmaceutical Product," "Be...
-- Winners to be Announced on 5th June at the Prix Galien UK Awards Ceremony in London
LONDON, May 13, 2025 /PRNewswire/ -- The Galien Foundation, the premier global institution dedicated to honouring innovators in life sciences, today announced the 2025 Prix Galien UK Award candidates for "Best Biotechnology Product," "Best Digital Health Solution," "Best Medical Technology," "Best Pharmaceutical Product," "Best Public Sector Innovation" and "Best Health Equity Innovation." Winners will be selected by a committee of distinguished scientific leaders and announced during the Prix Galien UK Awards Ceremony, on 5th June at the Natural History Museum in London. To learn more and secure your ticket to the event, please visit our website here.
"As Chair of the Prix Galien UK Committee, I am honoured to announce this year's exceptional candidates across six distinguished categories. These individuals and organisations exemplify excellence in healthcare innovation and demonstrate a steadfast commitment to advancing patient outcomes. Their contributions are shaping the future of medicine and reinforcing the vital role of scientific progress in improving human health," said Professor Sir Munir Pirmohamed, David Weatherall Chair of Medicine at the University of Liverpool and the NHS Chair of Pharmacogenetics, Chair of the Prix Galien UK Committee.
The Awards Committee is evaluating the product's innovation throughout its scientific development, clinical application and utility. Consideration is also given to the insights it has contributed to the advancement of biomedical science, as well as its measurable impact on human health.
"Each candidate reflects the unwavering pursuit of innovation in health and the enduring spirit of scientific achievement. We extend our congratulations to all those behind these transformative products, whose dedication continues to advance the promise of a healthier future for all," said Bruno Cohen, Chairman of The Galien Foundation.
The 2025 Prix Galien UK Award Candidates are as follows:
Best Biotechnology Product (Candidates)
Company | Product |
Immunocore | KIMMTRAK |
PTC Therapeutics | Upstaza™ |
Volition | Nu.Q® Vet Cancer Test |
Best Digital Health Solution (Candidates)
Company | Product |
Gulsine ltd. | A2P2 Platform |
HARLEYDOC | HARLEYDOC APP |
House of Possibility Limited (TRADING AS RAPID TAPPING) | Rapid Tapping® |
Kidney Beam Ltd | Kidney Beam |
Perspectum | CoverScan |
Prorizon Ltd. | Prorizon |
Viscera Technologies Ltd | Quantico |
Best Medical Technology (Candidates)
Company | Product |
Insulet Corporation | Omnipod® 5 Automated Insulin Delivery System |
Smith & Nephew Medical Ltd. | RENASYS EDGE |
THERMOTRAUMAPORT LTD | THERMOTRAUMAPORT |
Wellvii | Blood Pressure Finger Cuff |
Best Pharmaceutical Product (Candidates)
Company | Product |
Angelini Pharma UK-I Limited | ONTOZRY▼® |
AstraZeneca and Merck Sharp & Dohme (MSD) | LYNPARZA® |
Gilead Sciences Ltd | Sunlenca |
Incyte Biosciences UK Ltd | Opzelura® (ruxolitinib) 15 mg/g cream |
Johnson and Johnson | Rybrevant®▼ |
Novartis Pharmaceuticals UK | Iptacopan |
Roche Products Limited | Alecensa |
SANOFI | Rezurock |
Best Public Sector Innovation (Candidates)
Company | Product |
BioDundee | Dundee Life Sciences and Healthcare Innovation Ecosystem |
University of Glasgow | Wolbachia-based interventions for the biological control of dengue |
University of Liverpool | Liverpool's COVID-19 Trio: ISARIC (clinical characterisation), SMART (testing) and AGILE (trials) |
University of Liverpool and Liverpool University Hospitals NHS Foundation Trust | LDIR Wand |
University of Oxford | R21/Matrix-M Malaria Vaccine |
Well Cool Clothing Ltd | Well Cool Patient Wear |
Best Health Equity Innovation (Candidates)
Company | Product |
Agios Pharmaceuticals, Inc. | Clinical Trials Designed with Patients, for Patients: RISE UP Sickle Cell Disease Clinical Program |
bren | brain-to-brain intelligence (bbi) |
HARLEY of LONDON | Harley Wellness Dollar Empowering Community Health, Wellness and Lifestyle |
Kids Operating Room | Solar Surgery |
National Institute for Health and Care Excellence (NICE) | NICE technology appraisal guidance (TA1044) for exagamglogene autotemcel (exa-cel) for treating severe sickle cell disease in people 12 years and over. TA1044 |
Nuffield Department of Primary Care Health Sciences, University of Oxford | Centre for Research Equity - Embedding Equity into UK Health and Care Research: A National Collaborative Model for Inclusive Research Design and Delivery |
Pfizer Inc | Multicultural Health Equity Collective |
ProFactor Pharma | Affordable recombinant Factor VIII |
Sisters of Support CIC | Sisters of Support |
The Drug Discovery Unit, University of Dundee | Drug Discovery for Neglected Infectious Diseases |
The Prix Galien Awards were established in 1970 and launched in the UK in 1990 and have been awarded to 51 products since its inception. Winners are selected every year by the Prix Galien UK Awards Committee, which comprises 13 experts in the field, and includes a number of the UK's leading luminaries in healthcare. The distinguished panel is guided by the conviction that acknowledging research-driven innovation is key to the improvement of healthcare in the UK and human health, globally.
During the ceremony, the 2025 Prix Galien UK Lifetime Achievement Award will be bestowed upon Dame June Raine, Former Chief Executive, Medicines and Healthcare products Regulatory Agency. The keynote address will be delivered by Roland Sinker, Chief Executive at Cambridge University Hospitals NHS Foundation Trust.
Prix Galien UK Awards Committee 2025
Professor Sir Munir PIRMOHAMED
David Weatherall Chair of Medicine, University of Liverpool, NHS Chair of Pharmacogenetics
Committee Chair
Professor Jane ADAM
Honorary Professor, University of Exeter, Consultant Radiologist, St George's Hospital London and former Chair Technology appraisal committee, NICE
Professor Bruce CAMPBELL
Past Chair NICE Interventional Procedures and Medical Technologies Advisory Committees; Honorary Vascular Consultant and Professor, Exeter
Professor Jesse DAWSON
Professor of Stroke Medicine at School of Cardiovascular and Metabolic Health in the College of Medical, Veterinary and Life Sciences at the University of Glasgow; Consultant Physician in the Queen Elizabeth University Hospital, Glasgow
Doctor Stephanie KUKU
Chief Knowledge Officer - Conceivable Life Sciences, Senior Consultant – Hardian Health, Board Trustee – The Kings Fund, Honorary Senior Research Fellow, UCL
Professor Sudhesh KUMAR, OBE
Vice President (Health), University of Warwick and President of Association of Innovation, Research and Technology Organisations, UK (AIRTO)
Professor Andrew MORRIS, CBE
Director, Health Data Research UK & Professor of Medicine and Vice Principal Data Science, University of Edinburgh
Professor Sharon PEACOCK, CBE
Master of Churchill College Cambridge
Dame June RAINE
Former Chief Executive, Medicines and Healthcare products Regulatory Agency
Professor Duncan RICHARDS
Professor of Clinical Therapeutics, University of Oxford
Professor Bethany SHINKINS
Professor of Health Economics, Diagnosis and Screening
Doctor Lauren WALKER
Professor of Clinical Pharmacology & Therapeutics, University of Liverpool
Professor Dame Moira WHYTE
Sir John Crofton Professor of Respiratory Medicine, University of Edinburgh
About The Galien Foundation
The Galien Foundation fosters, recognises and rewards excellence in scientific innovation to improve the state of human health. Our vision is to be the catalyst for the development of the next generation of innovative treatments and technologies that will impact the state of medical practice and save lives.
The Galien Foundation oversees and directs the Prix Galien's activities in the UK as part of an international awards program dedicated to advancing innovative medicines development. The Prix Galien operates through chapters in 14 countries and Africa, with a new chapter launched in India in 2024 and plans for Prix Galien Japan in 2026. The Prix Galien was created in 1970 by Roland Mehl in honour of Galien, the father of medical science and modern pharmacology. Worldwide, the Prix Galien is regarded as the equivalent of the Nobel Prize in biopharmaceutical research.
For more information, visit www.galienfoundation.org.
Follow the Foundation on social media:
https://www.facebook.com/GalienFoundation/
https://twitter.com/GalienFdn
https://www.linkedin.com/company/the-galien-foundation/
Media Contact (UK):
Julian Tyndale-Biscoe
Finn Partners
Julian.Tyndale-biscoe@finnpartners.com
+44 20 3217 7060
Media Contact (Global):
Kara Bradley
Finn Partners
Kara.Bradley@finnpartners.com
646-213-7243
Logo - https://mma.prnewswire.com/media/564722/The_Galien_Foundation_Logo.jpg
View original content: